Breast Cancer Index® (BCI)
Use
NeoGenomics has partnered with Biotheranostics, a Hologic Company, to make ordering BCI easy for women with early‑stage hormone receptor‑positive (HR+) breast cancer. BCI is the only test recognized by the NCCN® Guidelines to predict which patients are likely to benefit from extended adjuvant anti‑estrogen therapy beyond 5 years.
Special Instructions
Not provided.
Limitations
Not provided.
New York Approved
Methodology
PCR-based (PCR)
Biomarkers
Unknown signature
Signature
Result Turnaround Time
10 days
Related Documents
For more information, please review the documents below
Specimen
Tissue (FFPE)
Volume
Not provided
Minimum Volume
Not provided
Container
Paraffin block or 3‑4 unstained 10 micron sections on glass slides plus one H&E slide
Collection Instructions
Primary invasive breast tumor, tumor area ≥40% neoplastic cells; exclude post‑treatment, FNA, fresh/frozen tissue, ER‑ and PR‑, positive nodes, microinvasive carcinoma, metaplastic/metastatic carcinoma, carcinosarcoma, sarcoma, neuroendocrine carcinoma, adenoid cystic carcinoma, phyllodes tumor, male gender, T4 tumor, no invasive carcinoma, biopsy from chest wall/skin/axilla/lymph node.
Storage Instructions
Use cold pack for transport; cold pack not in direct contact with specimen; NYS clients must provide date and time of collection.
Causes for Rejection
Specimens with clinical or specimen characteristics not acceptable as listed above.